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Abstract
Background: Leber’s hereditary optic neuropathy (LHON) is a maternally inherited disorder with point mutations in
mitochondrial DNA which result in loss of vision in young adults. The majority of mutations reported to date are within the
genes encoding the subunits of the mitochondrial NADH-quinone oxidoreductase, complex I. Establishment of animal
models of LHON should help elucidate mechanism of the disease and could be utilized for possible development of
therapeutic strategies.
Methodology/Principal Findings: We established a rat model which involves injection of rotenone-loaded microspheres
into the optic layer of the rat superior colliculus. The animals exhibited the most common features of LHON. Visual loss was
observed within 2 weeks of rotenone administration with no apparent effect on retinal ganglion cells. Death of retinal
ganglion cells occurred at a later stage. Using our rat model, we investigated the effect of the yeast alternative NADH
dehydrogenase, Ndi1. We were able to achieve efficient expression of the Ndi1 protein in the mitochondria of all regions of
retinal ganglion cells and axons by delivering the NDI1 gene into the optical layer of the superior colliculus. Remarkably,
even after the vision of the rats was severely impaired, treatment of the animals with the NDI1 gene led to a complete
restoration of the vision to the normal level. Control groups that received either empty vector or the GFP gene had no
effects.
Conclusions/Significance: The present study reports successful manifestation of LHON-like symptoms in rats and
demonstrates the potential of the NDI1 gene therapy on mitochondrial optic neuropathies. Our results indicate a window of
opportunity for the gene therapy to be applied successfully after the onset of the disease symptoms.
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Introduction
Leber’s hereditary optic neuropathy (LHON) is a hereditary
optic atrophy that is characterized by an acute or subacute loss of
central vision [1,2]. By the time the disease is fully developed, the
retinal ganglion cells die and the eyes and optic nerves become
atrophied although a relative pupillary light reflex remains [3,4].
Wallace et al reported for the first time that LHON was related to a
point mutation in the mitochondrial DNA (mtDNA) [5].
Approximately 95% of LHON have one of three point mutations
in the genes encoding subunits of the mitochondrial proton-
translocating NADH-quinone oxidoreductase (complex I) which
are G3460A (ND1), G11778A (ND4), and T14484C (ND6) [6].
Other complex I subunits known to be related to LHON include
ND4L and ND5 [7].
In an effort to clarify mechanism of LHON and possible
development of therapeutic strategies, animal models of LHON
have been created in rodents. They were based on either direct
exposure of complex I inhibitor into the eye [8], or transduction of
iRNA for the NDUFA1 subunit of complex I in the mouse retina
[9], and allotopic expression of the mutated human ND4
(G11778A) gene in the rat retina [10]. These models exhibited
degeneration of the retinal ganglion cell layer and the optic nerve
of rodents, suggesting that complex I deficiencies in the retinal
ganglion cells are associated with LHON symptoms. However, it is
unclear whether LHON is somagenic or axogenic [11]. As
described above, the available LHON animal models were raised
by injection of causative factors (complex I inhibitor, iRNA for the
NDUFA1 subunit or the mutated human ND4 gene) into eyes.
Here, we report a rat animal model that relied on the
administration of complex I inhibitor, rotenone, in the optical
layer of the superior colliculus (SC) of the brain where the retinal
ganglion cells project their nerve terminals. The animals tested
developed symptoms that resembled main clinical features of
LHON documented so far.
At present, it seems difficult to repair mitochondrial DNA.
Therefore, an allotopic strategy has been used to circumvent this
problem. Since polypeptides encoded by mtDNA are highly
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expressed polypeptides in cytoplasm and triggering immune
response by over-expressed hydrophobic subunits in the
cytoplasm. Regardless of defects of mtDNA- and nuclearDNA-
encoded subunits of complex I, the alternative NADH dehydro-
genase (Ndi1) from yeast mitochondria can restore NADH
oxidase deficiencies and suppress reactive oxygen species (ROS)
overproduction caused by complex I defects. In fact, we and other
laboratories had previously demonstrated that the Ndi1 enzyme
worked as a functional replacement for defective complex I in
various mammalian culture cells [12–23]. In addition, the Ndi1
expression protected against complex I deficiencies of animals. So
far, the NDI1 gene has been shown to prevent or retard disease-
like symptoms caused by complex I deficiencies [24–29]. In this
paper, we report the first successful amelioration by the NDI1 gene
in a rat animal model.
Results
LHON-like features manifested in rats by administration
of rotenone into the brain
We investigated the effect of rotenone administration into the
rat brain and injection of an adeno-associated virus (type 5)
carrying the NDI1 gene (rAAV5-NDI1) by monitoring the
histopathological hallmarks of the disease using Long Evans male
rats. Rats were divided into 11 groups (Table 1). Both rotenone
microspheres (3 ml per site) and viral particles (rAAV5-NDI1,
rAAV5-GFP, or rAAV5-empty vector, 3 ml per site) were infused
bilaterally in the optical layer of the SC of the rat brain. The eyes
and brains were processed for immunohistochemistry 2 months
after the initial treatments unless otherwise specified. The most
common features of LHON, the optic nerve and retina atrophy,
were identified in the rotenone-treated animals. Indeed, the
microspheres releasing the complex I inhibitor elicited damage to
the optic nerve and the retina. It should be noted that, unlike the
subcutaneous injection of rotenone microspheres [25], no
rotenone was detected in the blood stream of the animal. The
retina of the rotenone-treated rats was significantly thinner than
that of the control (Figure 1). The loss occurred mainly in the inner
plexiform layer and the inner nuclear layer. The number of the
retinal ganglion cells was also diminished compared to the control.
The reduction of the retina thickness was not accompanied by any
obvious inflammatory process. No immune cell infiltration was
seen within the retina or the optic nerve. The optic nerve lost an
average of 20% in diameter compared to the control (Figure S1).
Electron microscopy of the optic nerve of rotenone-treated rats
revealed disorganization of the neuronal fibers, axons of the retinal
ganglion cells as well as some demyelination (Figure 2C).
Expression of Ndi1 in the retinal ganglion cells and the
optic nerve in rats
Our objective was to achieve efficient introduction of the Ndi1
protein in the mitochondria of the whole retinal ganglion cell
layer, axons, and the nerve terminals. We first attempted injections
of rAAV5-NDI1 directly into the eye. However, this method was
not reliable because the expression areas were dependent on the
location of the injection and a complete spread throughout the
entire retina was not always possible. On the contrary, injections of
the same rAAV5-NDI1 to the SC where the terminals of the optic
nerves are located gave rise to a consistent expression of Ndi1 in
the entire region of our target. Within 2 months, Ndi1 was fully
expressed in all regions of the SC, the optic nerve (including the
chiasma and the entry point into the eye), and the retinal ganglion
cell layer (Figure 3). It should be noted that we could detect Ndi1
as early as 1or 2 weeks after the rAAV5-NDI1 injection albeit at a
much lower level (Figure S2). The Ndi1 expression matched the
pattern of the mitochondrial network of the cell. The presence of
Ndi1 did not result in any apparent change when compared to the
control group in terms of the thickness of the retina (Figure 1B)
and morphology of myelin sheath surrounding the axons
(Figure 2B). The expression of Ndi1 was sustained for at least 6
months in rats and up to 20 months in mice.
Protective action of Ndi1 against the deleterious effect of
rotenone
First, we evaluated the effect of expressing Ndi1 on the
morphological damage by rotenone. When the rats received
rAAV5-NDI1 at the time of rotenone administration, the thickness
of the retinal ganglion layer remained normal compared to control
and the overall organization of the retina was conserved
(Figure 1d). Similar protective effect was observed even when
the rAAV5-NDI1 injection was done 1 or 2 weeks after the
initiation of rotenone administration (Figure 1e and 1f). Similarly,
no degeneration was identified in the structure of the optic nerve
axon in the groups of rats injected with rAAV5-NDI1 in addition
to rotenone (Figure 2d). In contrast, rAAV5-GFP or rAAV5-
empty vector did not have any effect (Figure 1g, 1h, 1i, and 1j).
Table 1. Animal groups and treatments.
Group Treatment Number of animals
None rats did not receive any treatment 5
aav-GFP rats were injected with rAAV5- GFP 4
aav-NDI1 rats were injected with rAAV5- NDI1 5
Rotenone rats received an injection of rotenone microspheres 5
Rotenone + aav-NDI1 rats were injected with rAAV5-NDI1 2 days after the rotenone administration 5
Rotenone + aav-GFP rats were injected with rAAV5-GFP 2 days after the rotenone administration 4
Rotenone + aav rats were injected with rAAV5-empty vector 2 days after the rotenone administration 4
Rotenone-1w-aav-NDI1 rats received rAAV5-NDI1 injection 1 week after the rotenone administration 5
Rotenone-2w-aav-NDI1 rats received rAAV5-NDI1 injection 2 weeks after rotenone administration 5
Rotenone-2w-aav-GFP rats received rAAV5-GFP injection 2 weeks after rotenone administration 4
Rotenone-2w-aav rats received rAAV5-empty vector injection 2 week after rotenone administration 4
doi:10.1371/journal.pone.0011472.t001
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myelin basic protein (MBP) in the optic nerve by approximately
20% of control (Figure 4). The group of rats that received rAAV5-
NDI1 retained the content of MBP.
Restoration by Ndi1 of impaired vision of rotenone
treated rats
Next, we examined the blindness of the rats by a T-maze
behavior test (Figure S3). The non-treated rats (control group) had
a strong preference to the dark side as expected. The group of rats
that received rotenone still demonstrated a strong preference for
the dark side. In other words, the damage caused by rotenone
administration to the optic nerve and the retina was not sufficient
to provoke total blindness in the rats. Therefore, a more sensitive
test was used to evaluate their vision [30]. The testing involved
monitoring for head tracking response with an animal placed in an
optokinetic apparatus, and was performed at a fixed interval after
rotenone administration (Movie S1). The rotenone group showed
a gradual decrease of the head tracking score (time of head
tracking in second) which reached the lowest level between the
third and the fourth week of the treatment (Figure 5). The group
injected with the rAAV5-NDI1 in addition to rotenone exhibited
optokinetic scores that closely followed those of the control group.
Remarkably, the animals that received the rAAV5-NDI1 injection
1 week after the rotenone administration increased their
optokinetic scores and reached the level of the control group on
week 4. A similar recovery of vision was achieved with the group
that received the rAAV5-NDI1 injection 2 week after the rotenone
treatment. In the latter case, a complete recovery took place on
week 7. Injection of rAAV5-GFP or rAAV5-empty had no
observable effect. Figure 5B summarized results of optokinetic
experiments 8 weeks postinjection of rotenone. It is apparent that
rAAV5-NDI1 can completely rescue the animals from vision loss
but the control vectors (rAAV5-GFP or rAAV5-empty vector)
cannot. This is the first report in which the NDI1 gene was shown
to cure symptoms caused by complex I deficiencies in an animal
model. These results strongly suggest the great potential of the
NDI1 gene as a therapeutic agent for vision loss caused by complex
I deficiency. It was suspected that, at earlier stages (1–2 weeks) of
the rotenone treatment, there is already some damage to the retina
or the optic nerve that causes impairment of vision but that
damage is still restorable. We have examined tissues of rats 2 and 4
weeks after rotenone microspheres injection. No cell death was
detected in the ganglion cell layer of the retina of rats 2 weeks after
rotenone injection, but significant cell death was detected in rats 4
weeks post injection of rotenone (Figure S4). In addition, we
looked for a sign of ROS formation by visualizing oxidized DNA.
Both the retina and the optic nerve showed positive results after 2
weeks of rotenone exposure (Figure S5). This agrees with our
previous observations that, both in vitro and in vivo, generation of
Figure 1. Representative images of the rat retina after rotenone exposure and the effect of rAAV5-NDI1. Microspheres loaded with
rotenone was injected into the SC of rat brain. Two months later, the retina was examined for damage using hematoxylin-eosin staining. A,
representative images of the retina; B, comparison of the cell layer thickness of the retina. The histogram shows the average of the thickness of the
retina cell layers after hematoxylin-eosin staining (n=4 for rats, n=16 for retina slices from each rat retina). For both Figure 1A and 1B, a, control; b,
rAAV5-NDI1 injection only; c, rotenone microspheres injection only; d, rAAV5-NDI1 injected immediately after the rotenone-beads administration;e ,
rAAV5-NDI1 injected 1 week after the rotenone microspheres administration; f, rAAV5-NDI1 injected 2 weeks postadministration of rotenone
microspheres; g, rAAV5-GFP injected immediately after the rotenone microspheres administration; h, rAAV5-empty vector injected immediately after
the rotenone microspheres administration; i, rAAV5-GFP injected 2 weeks after the rotenone microspheres exposure; j, rAAV5-empty vector injected 2
weeks after the rotenone microspheres administration. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer
plexiform layer; ONL, outer nuclear layer. *p,0.05, **p,0.01, Student T-test compared to the same retina layer of control (a).
doi:10.1371/journal.pone.0011472.g001
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[25,31].
Prevention by Ndi1 of the cell death within the ganglion
cell layer and the SC
The brain slices of the rats, sacrificed 2 months after rotenone
administration, were stained with neuron specific antibody NeuN
and the number of neuron cells remaining in the optic layer of the
SC was counted (Figure 6A). In all animals tested, only the
rotenone group showed a significantly reduced number of
neurons. In parallel, we estimated the amount of astrocytes using
antibody against the glial fibrillary acidic protein (GFAP)
(Figure 6B). The rotenone group had a higher number of
astrocytes in the SC compared to others. A significant increase
of GFAP positive cells in samples of the rotenone-2w-aav-NDI1
animals group is also noticed. The number of retinal ganglion cells
was assessed for all animals used in this study. After hematoxylin-
eosin staining of the sagittal section of the eyes, retinal ganglion
cells were counted within an area spanning 100 mm. Those areas
were randomly chosen covering the entire retina. Figure 6C shows
that the Ndi1 expressing animals did not lose cells whereas the
group of animals treated with only the complex I inhibitor lost
approximately 55% of the retinal ganglion cells when compared to
the control group.
It has been shown that complex I dysfunction is related to the
cell apoptosis driven by mitochondria. In order to determine the
type of cell death occurring in the retina after rotenone treatment,
we searched for apoptosis hallmarks in the tissue samples. The
retina was stained with antibodies specific for the cleaved active
form of caspase 3, the cleaved form of caspase 9 or single-stranded
DNA (ssDNA). Figure 7 clearly shows a higher number of the
apoptotic marker (ssDNA) within the retina of the rotenone-
treated group whereas no or few positive staining was seen in the
other animals (see also Figure S6).
Retention of ATP and suppression of ROS generation by
Ndi1 in RGC-5 cell line
We next explored the physiological basis for the observed
protective effects exerted by Ndi1 expression using an in vitro
system. A retinal ganglion cell line (RGC-5 cells) stably expressing
Ndi1 was established for this purpose. When the RGC-5 cells were
incubated in the presence of rotenone, the cellular ATP content
dropped significantly within 8 hours and reached almost zero in
18 hours. The Ndi1-expressing RGC-5 cells exhibited a somewhat
reduced level of ATP but were able to sustain that level in the
presence of rotenone (Figure 8A). On the contrary, and in a
predicted manner, FCCP, an uncoupler that dissipates proton
gradient, rapidly exhausted ATP regardless of the presence of
Ndi1 (Figure 8B). Furthermore, RGC-5 cells incubated with
rotenone gave rise to ROS production as illustrated in
Figure 8C. The cells expressing Ndi1, however, showed no
detectable ROS production. Finally, the respiratory activity was
assessed by measuring mitochondrial consumption of oxygen using
digitonin-permeabilized cells (Figure 8D). Addition of complex I-
dependent substrates, glutamate plus malate, to the RGC-5 cells
expressing Ndi1 accelerated the respiration rate and the enhanced
activity was not inhibited by rotenone. The addition of succinate, a
substrate for complex II, generated about the same respiration rate
between the control and Ndi1-expressing cells. In all measure-
ments, the RGC-5 cells expressing the GFP protein behaved
exactly the same as the non-transduced control cells.
Discussion
The animal models of LHON reported so far dealt with the
retinal ganglion cell body as the target [8,10]. It is currently
unknown whether the disease is somagenic or axogenic [11]. Use
of microspheres allows a slow, persistent and long-term release of
rotenone. Our earlier study indicated that a subcutaneous
Figure 2. Electron micrographs of the optic nerves displaying the status of myelination. Rats were injected with rotenone-microspheres
or rAAV5-NDI1 or both as described for Figure 1. The optic nerve was examined 1 month after the rotenone infusion. A: control (no injection). B:
rAAV5-NDI1-injected. C: rotenone microspheres-injected. Parts of degenerated myelin are indicated by arrows. D: rotenone microspheres-treated
with a simultaneous injection of rAAV5-NDI1.
doi:10.1371/journal.pone.0011472.g002
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sustained level of rotenone in the blood for at least 2 months [25].
When the rotenone-loaded microspheres were injected into the
SC, the rotenone effect was observed in the entire population of
the ganglion cells in the retina. There are at least two points that
need to be discussed in relation to the actual disease. One is that
the rats treated with rotenone did not show complete blindness
because they were still able to distinguish between the light and the
dark environment in the T-maze test. This is consistent with the
observation that, in human LHON, patients suffering from
degraded visual acuity are able to preserve a pupillary reflex to
the light [3,4]. The other point is that, after 2 weeks of exposure to
rotenone, the rats severely lost their vision with no discernible
damage to the ganglion cell layer. At this stage, there was an
indication of ROS generation in both the retina and the optic
nerve axon. This is presumably caused by the action of rotenone
but did not seem fatal to the cells. Delivering the NDI1 gene at this
point restored the vision to the normal level within several weeks.
These results are especially important in light of the fact that
spontaneous recovery of visual acuity does occur in some LHON
patients (but rare) even yearsaftertheonsetofthe disease [6,32–34].
There aretwo distinct (acuteand atrophic) phasesin LHON. In the
acute phase, the blurring of vision appears, the perception of colors
is altered, and visual acuity of the patients is severely reduced. After
the acute phase, the retinal nerve fiber layer degenerates, the eyes
and optic nerve becomes atrophied, and vision remains severely
impaired in the atrophic phase [35,36]. Carelli et al. [6] reported
oligodendrocytic cytoplasmic tongues wrapping denuded axons,
strongly suggestive of ongoing axonal remyelination in the patients
with restored vision. These findings illustrate a dynamic process
occurring with the surviving axons in LHON and may well be
represented in our rat model. These results indicate that there exists
a window of opportunity for the gene therapy to be applied
successfully before the loss of cells.
It is well recognized that defects of complex I lead to two
consequences: (1) decrease of the membrane potential across the
inner mitochondrial membrane and the resultant impairment of
ATP synthesis; (2) ROS overproduction that causes oxidative stress
and apoptosis [21,37–39]. At the present time, it is unclear which
is the major event in the retinal ganglion cells in LHON. Our in
vitro experiment using the RGC-5 line showed a severe loss of
ATP, which agrees with the results reported for cellular models of
LHON [40,41]. On the other hand, a number of studies, including
our own, suggested involvement of apoptosis in which ROS
overproduction plays a critical role [21,42]. As we demonstrated
previously, the Ndi1 enzyme is able not only to restore electron
transfer pathway but to suppress ROS overproduction from
defective complex I [21,31]. In other words, the dual role of Ndi1
makes it an effective therapeutic molecule regardless of the nature
of the link between complex I dysfunction and manifestation of the
disease. In addition, it is conceivable that the ATP level sustained
by Ndi1-linked respiration is enough to prevent dysfunction
caused by complex I defects in retinal ganglion cells.
One of the important findings in this paper is that the NDI1
expression restored vision to the animals in our rat model. This
fact might stimulate a possibility of transkingdom gene therapy
Figure 3. Expression of the Ndi1 protein throughout the optic nerve system. Rats received rAAV5-NDI1 in the SC. Two months after the
injection, tissues were collected from the locations depicted in the cartoon (A – E) and immunohistochemically stained for the Ndi1 protein (green).
Nuclei were visualized by DAPI (blue). A1: coronal section of the optical layer (OL) of the superior colliculus (SC). Scale bar =150 mm. A2: optical layer
of the SC. Scale bar =40 mm. B: sagittal section of the optic chiasma. Scale bar =100 mm. C: sagittal section of the optic nerve. Scale bar =100 mm. D:
entry point of the optic nerve into the retina. Scale bar =40 mm. E1: transversal section of the retina. Scale bar =40 mm. E2: a high magnification
image of the retinal ganglion cell layer, Scale bar =10 mm.
doi:10.1371/journal.pone.0011472.g003
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M. et al., unpublished results) suggest that the Ndi1 expression
scarcely stimulate inflammatory or immune response in rats or
nonhuman primates (see reviews [12,43,44]). It is generally
accepted that transgene expression mediated by an adeno-
associated virus takes several weeks before reaching an optimal
level [45]. In this study, it was noticed that there was a sign of
recovery of the vision as early as 1 to 2 weeks after the rAAV5-
NDI1 injection into the animals that were displaying severe
impairment by rotenone treatment. The level of Ndi1 expression 1
week after the rAAV5-NDI1 injection was considerably lower than
that observed 1 or 2 months after the injection. This may imply
that a small amount of Ndi1 might be sufficient to compensate for
the reduced complex I activity. In addition, the Ndi1 protein
seems to have a long lasting expression in the retinal ganglion cells
as we were able to detect it even 6 months after the injection.
Together with the fact that the adeno-associated virus strategy was
successfully used to treat retinal degeneration in human [46–48], it
is conceivable that use of the NDI1 gene may prove to be a




Eight weeks old Long Evans male rats (Charles River, Reno)
were housed 2 per cage in a 12 hours light/dark cycle and were
fed with food and water ad libitum. All procedures were approved
by the Institutional Animal Care and Use Committee (IACUC) at
The Scripps Research Institute (approval ID 08-0065). Stereotaxic
injections were performed under isoflurane anesthesia. Three ml
Figure 4. Loss of myelin in the optic nerve of rotenone-treated
rats and its protection by rAAV5-NDI1. Sagittal sections of the
optic nerve were obtained from the rats treated with rotenone for 8
weeks and were stained for myelin basic protein (MBP) using specific
antibody. A: representative pictures of the MBP staining intensity. Scale
bar =100 mm. B: histograms comparing the fluorescence intensity of
MBP staining. MBP staining intensity was evaluated by ImageJ (NIH)
with 8 measures per animal and 4 animals per group. **p,0.01, n.s. (no-
significant) Student’s T-test. Error bars represent the mean 6 SD. For A
and B: a, control; b, rats treated with rotenone for 8 weeks; c, rAAV5-
NDI1 injected immediately after the rotenone microspheres.
doi:10.1371/journal.pone.0011472.g004
Figure 5. Optokinetic tests of rotenone-treated rats exhibiting loss of vision and the protective and ameliorative effects by Ndi1.
Rats were injected with rotenone microspheres in the SC as described for Figure 1. Optokinetic tests were performed every week for the duration of
the treatment. Each rat was monitored for 2 minutes and the time of head tracking response was counted to compute the optokinetic score. A: time
dependent change of optokinetic scores of rats with various treatments. B: comparison of optokinetic scores of all rat groups at week 8. Treatments
of the individual group of rats are as follows: a, control (no injection); b, control (rAAV5-GFP injection at week 0); c, rAAV5-NDI1 injection at week 0;d ,
rotenone injection at week 0; e, rotenone injection at week 0 and rAAV5-NDI1 at day 2; f, rotenone injection at week 0 and rAAV5-NDI1 injection at
week 1; g, rotenone injection at week 0 and rAAV5-NDI1 injection at week 2; h, rotenone injection at week 0 and rAAV5-GFP injection at day 2; i,
rotenone injection at week 0 and rAAV5-empty vector injection at day 2; j, rotenone injection at week 0 and rAAV5-GFP injection at week 2; k,
rotenone injection at week 0 and rAAV5-empty vector injection at week 2. *p,0.05, ANOVA test excluding the rotenone-treated group.
doi:10.1371/journal.pone.0011472.g005
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NDI1 (serotype 5, 3.1610
12 genome copy/ml, Applied Viromics)
were infused at 350 nl/min into the optical layer of the SC
bilaterally (coordinates for the Bregma: antero-posterior
20.63 cm; media-lateral 60.15 cm; dorso-ventral 20.36 cm).
rAAV5-NDI1 was prepared as described previously [16]. As
control vectors, rAAV5-GFP and rAAV5-empty (serotype 5,
3.1610
12 genome copy/ml, Applied Viromics) were also prepared
following the preparation method of rAAV5-NDI1.
Rotenone microspheres production
Biodegradable microspheres containing rotenone were pre-
pared as described previously [25] with modifications. Briefly,
200 mg of rotenone was dissolved with 200 mg of poly(DL-lactide-
co-glycolide) (Sigma, lactide:glycolide 75:25, mol wt 90,000–
126,000) in 7 ml of dichloromethane. The organic phase was
poured into ice-cold 8% (w/v) polyvinyl alcohol (hot water soluble;
Sigma). The microspheres were collected by decantation and only
the top layer of the microspheres was retrieved and washed with
sterile distilled water. The average size of the beads was estimated
to be ,8 mm.
Behavioral studies. The T-maze test was used to evaluate
the capacity of the rats to distinguish between dark and light fields
(www.ratbehavior.org/RatsAndMazes.htm). The maze was placed
under bright light and one of the ends was covered to create a dark
spot in such way that the animal is allowed to choose between the
light and the dark side. Each animal was tested 15 times (3 each at
5 separate times) with occasional swapping of the two sides to
prevent preferences. The optokinetic test was performed to assess
the vision of the animals in a scalable manner [30]. This test
consisted of placing a rat in a squared transparent cage surrounded
by 4 monitors linked to a computer. The monitors displayed a
pattern of vertical black and white strips which move from side to
side at a defined speed. The screens were 800 pixels wide. The
black and white strips were 60 and 75 pixels wide, respectively.
The direction was switched every 4 seconds. The head tracking
response of the rat was monitored for 2 minutes. Each test was
videotaped for analysis (see Movie S1 for an example).
Electron microscopy
Rats were euthanized, under a high dose of Pentothal, by
transcardiac perfusion of phosphate buffered saline (PBS) followed
by a fixative consisting of 1% paraformaldehyde with 3%
glutaraldehyde in 0.1 M cacodylate with the addition of 1 mM
calcium chloride. The eyes were removed and continued with
Figure 7. Prevention of apoptosis of cells treated with
rotenone by Ndi1 expression. Rats were subjected to rotenone
exposure for 2 months as detailed in the legend to Figure 1 and the
retina samples were stained for single strand DNA (red) and DAPI (blue).
A: (a) control (no injection), (b) rAAV5-NDI1 injected animal, (c)
rotenone microspheres injected animal, (d) rAAV5-NDI1 was injected
immediately after the rotenone administration, (e) rAAV5-NDI1 was
injected 1 week after the rotenone administration, (f) rAAV5-NDI1 was
injected 2 weeks after the rotenone administration. The arrows
highlight some of the cells carrying the apoptotic marker. Bright
fluorescence seen in the cones and rods layer of the retina is un-specific
and is not considered for ssDNA evaluation. B: The number of retinal
ganglion cells positive for ssDNA staining was compiled in a histogram.
Cells were counted per field of view in different sections separated by at
least 100 mm. **p,0.0001, ANOVA test. Error bars represent the
mean6SD.
doi:10.1371/journal.pone.0011472.g007
Figure 6. Loss of neurons and retinal ganglion cells caused by
rotenone treatment. Rats were subjected to rotenone exposure for 2
months as detailed in the legend to Figure 1. A and B: Tissue sections of
the optical layer of the SC were stained with specific antibodies
targeting neurons (NeuN) and astrocytes (GFAP), respectively. C: after
hematoxylin-eosin staining, the retinal ganglion cells of the GCL were
counted. Cells were counted per field of view in 64 different sections
separated by at least 100 mm. *p,0.05, **p,0.001, one way ANOVA
test. Error bars represent the mean6SD.
doi:10.1371/journal.pone.0011472.g006
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eyecup were dissected free of muscles, washed in a buffer, and
postfixed in 1% OsO4 in 0.1 M cacodylate buffer with 3.5%
sucrose. Tissues were subsequently washed in distilled water,
dehydrated in a graded ethanol series followed by transitioning in
propylene oxide and embedded in Embed 812/Araldite (Electron
Microscopy Sciences, Hatfield PA). Initially, thick (1.5 mm)
sections of the optic nerves were cut and stained with toluidine
blue for light microscopy assessment. Subsequently, transverse thin
sections (60 nm) of the optic nerves were cut with a diamond knife
(Diatome, Hatfield PA), mounted on copper slot grids coated with
parlodion and stained with uranyl acetate and lead citrate for
examination on a Philips CM100 electron microscope (FEI,
Hillsbrough OR). Images were documented using a Megaview III
ccd camera (Olympus Soft Imaging Solutions, Lakewood CO).
Histological analysis
Rats were euthanized under a high dose of Pentothal, by
transcardiac perfusion of PBS following by 4% paraformaldehyde
(v/w in PBS, pH 7.4). The brains and eyes were retrieved and
cryoprotected, overnight at 4uC, in 20% sucrose (v/w in PBS,
pH 7.4). Tissue samples were sliced using a cryostat at 30 mm
(brains) or 12 mm (eyes). Each slice was collected onto Superfrost
slide (Fisher) and stored at 220uC. For immunohistological
procedures, antigen retrieval was carried out as follows: the slides
were placed in a preheated solution of 1 mM EDTA, 10 mM Tris-
Cl, pH 8 and micro-waved for 15 minutes at 85–90uC. The
solution was cooled down to room temperature in 10 minutes and
the slides were transferred to PBS for staining. The samples were
blocked using Tris buffered saline (TBS, pH 7.8) containing 10%
horse serum, 0.1% Triton X-100 for 1 hour and then incubated
overnight at 4uC with primary antibodies in TBS, 10% horse
serum, 0.1% Triton X-100. Antibodies used are Ndi1 (1/500),
NeuN (1/200); GFAP (1/400); ssDNA (1/200), and cleaved
caspase3/9 (1/400) from Cell Signaling; MBP (1/200) from
Chemicon; 7,8-dihydro-8-oxo-deoxyguanine (8-oxo-dG) (1/300)
from Cosmo Bio Co, Japan. After 3 washes with PBS, secondary
antibodies were applied on the section for 2 hours at room
temperature. The Ndi1 antibody was revealed with a specific
horseradish peroxidase conjugated antibody (1/1000; Calbio-
chem) and the TSA Plus fluorescein system kit (PerkinElmer).
Histochemical staining for 8-oxo-dG (1/300 dilution, Cosmo Bio
Co., Japan) was performed as described before [25] with minor
modifications: endogenous peroxidase activities were eliminated
by incubation of the tissue samples in methanol 3% H2O2 for
30 min and the Tyramide Signal Amplification kit (TSA,
Amersham) was used according to the manufacturer’s instructions.
Hematoxylin-Eosin staining
H&E staining was performed on frozen section as described
previously [20]. The sections (10–30 mm) on slides were immersed in
xylene (10 min, twice), and rehydrated in a decreasing ethanol series
diluted in distilled water (100%, 100%, 95%, 95%, 75%, 0%, 1 min
each). The sections were rinsed in deionized water, stained in
hematoxylin for 45 sec, rinsed in deionized water, and finally stained
in eosin for 1 sec. After the color reaction, sections were dehydrated
through an ethanol series into xylene and mounted using Permount
mounting medium (Fisher Scientific, Pittsburgh, PA).
Figure 8. Compensatory effect by Ndi1 on complex I inhibition in RGC-5 cells. A and B, cellular ATP level. RGC-5 cells with or without
expressed Ndi1 or GFP were grown in 6 well plates and incubated for the indicated time with 100 nM rotenone (A) or 1 mM FCCP (B). The ATP content
of the cells was evaluated using the luciferase assay system. Error bars represent the mean6SD. C, MitoSox staining of RGC-5 cells incubated with
100 nM of rotenone for 8 hours. RGC-5 cells were incubated in the absence (a) or presence (b) of the complex I inhibitor. RGC-5 cells expressing Ndi1
were incubated in the absence (c) or presence (d) of rotenone. D, Oxygraphs showing the respiratory activity of RGC-5 cells. Cells were permeabilized
by digitonin treatment. The measurements were performed with 1610
7 cells per assay. Respiratory substrates and inhibitors were added sequentially
at the concentrations given in Materials and Methods. The rate of oxygen consumption is shown in mMO 2/min.
doi:10.1371/journal.pone.0011472.g008
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Eye slices were incubated in a solution containing 2 mg/ml
nitro blue tetrazolium, 0.5 mM NADH, 50 mM Tris-Cl, pH 7.6
at 37uC for 15 min. The tissues were washed 2 times with TBS
and destained with a series of increasing concentration of acetone
solutions (30%, 60%, 90%). The slices were dried and mounted
with Permount (Fisher).
ATP measurements and MitoSox staining on RGC-5 cells
The RGC-5 cell line, kindly provided by Dr. Agarwal of UNT
Health Science Center [49] were maintained in DMEM 10%
horse serum at 37uC, 5% CO2. For the experiments, the cells were
cultured in 6 well plates and incubated under the conditions
described in the result section. The cells were scraped in PBS
poured into centrifuge tubes and the total protein concentration
was determined. For ATP measurements, ice cold perchloric acid
(2M, 500 ml) was added to the cell suspension and, after 5 minutes,
175 ml of 1M Bicine and 306 ml of potassium hydroxide (4M) were
added. The tubes were kept on ice for 15 minutes. After
centrifugation, the ATP concentration was determined on the
supernatant using the ATP Determination Kit (Invitrogen).
Production of reactive oxygen species (ROS) in mitochondria
was visualized by MitoSox (Invitrogen) staining using live cells as
follows: cultured RGC-5 cells were incubated with or without
100 nM of rotenone for the indicated period of time. The MitoSox
reagent was diluted to a final concentration of 1.5 mM in warm
DMEM 1% serum and added to the cells. After 10 minutes, cells
were fixed with 4% paraformaldehyde for 10 minutes, mounted
onto glass slides with Mowiol mounting medium, and observed
under a Zeiss fluorescence microscope by using excitation
510 nm/emission 580 nm.
Oxygen consumption measurements on RGC-5 cells
The cells were harvested by trypsinization and resuspended in
1 ml of a medium containing 20 mM Hepes, pH 7.1/250 mM
sucrose/10 mM MgCl2. The cells were treated with digitonin until
more than 90% of the cells are stained by trypan blue. The
digitonin-treated cells were washed with the same medium.
Oxygen consumption was measured polarographically in 0.6 ml
of a buffer containing 20 mM Hepes, pH 7.1/250 mM sucrose/
10 mM MgCl2 by using a Clark electrode in a water-jacketed
chamber maintained at 37uC. Concentrations of substrates and
inhibitors used were: 5 mM glutamate, 5 mM malate, 5 mM
rotenone, 5 mM succinate, 5 mM antimycin A, and 0.5 mM
flavone.
Analyses
The image intensity was analyzed by ImageJ (NIH). Statistic
analyses of the experimental data were performed by using
appropriate test from Student t test, one-way or post hoc ANOVA.
Supporting Information
Figure S1 Effect of rotenone administration on the diameter of
the optic nerve. Rats were subjected to rotenone exposure for 2
months as detailed in the legend to Figure 1. A: Representative
pictures of sections of the optic nerve stained with hematoxylin-
eosin. B: The diameter of the largest portion of each tissue was
determined and compiled into histograms. *p,0.05, Student’s T-
test. Error bars represent the mean6SD.
Found at: doi:10.1371/journal.pone.0011472.s001 (2.67 MB TIF)
Figure S2 Expression of the Ndi1 protein in the retinal ganglion
cells and the optic nerve of the rat 1 week and 1 month after
receiving rAAV5-NDI1. The presence of Ndi1 was evaluated by
the NADH dehydrogenase activity and TSA-enhanced antibody
staining of the retina and the optic nerves of rats. Tissue samples
were collected 0, 1 week, and 1 month after injection of rAAV5-
NDI1 into the superior colliculus. Scale bar =50 mm. Histograms
on the right compare the number of RGC that are expressing
Ndi1 between the1 week and the 1 month retina samples.
*p,0.05, Student’s T-test. Error bars represent the mean6SD.
Found at: doi:10.1371/journal.pone.0011472.s002 (2.10 MB
TIF)
Figure S3 Behavioral study to assess vision of treated rats. Rats
were subjected to rotenone exposure for 1 month as detailed in the
legend to Figure 1. The animals were evaluated for their capacity
to distinguish the dark and the light environment. In a bright
room, animals were placed in a T-maze in which one of the ends
was covered to create a dark section. Normal rats rush to the dark
section in order to escape from the stress of the bright
environment. Error bars represent the mean6SD.
Found at: doi:10.1371/journal.pone.0011472.s003 (0.07 MB TIF)
Figure S4 Time-dependent induction of apoptosis in the
ganglion cell layer by rotenone administration. Rats were
subjected to rotenone exposure as detailed in the legend to
Figure 1. The retina was stained for TUNEL (green) or DAPI
(blue). Arrows highlight the TUNEL-positives nuclei. Scale bar
=40mm.
Found at: doi:10.1371/journal.pone.0011472.s004 (1.12 MB TIF)
Figure S5 Early events of ROS generation caused by rotenone
exposure. Rotenone-loaded microspheres were infused bilaterally
in the optical layer of the superior colliculus of the rat brain. Two
weeks after the injection, the optic nerve and the eyes were
processed for histochemical assays. DNA oxidation in the
respective tissues was assess by histochemical staining using
antibody against 8-oxo-dG (green). Nuclei were visualized with
DAPI (blue). Oxidative damage can be seen in the tissues from
rotenone-treated rats. Scale bar =15 mm.
Found at: doi:10.1371/journal.pone.0011472.s005 (0.53 MB TIF)
Figure S6 Caspase activation in ganglion cell layer induced by
rotenone treatment. Rats were subjected to rotenone exposure for
2 months as detailed in the legend to Figure 1. The retina of the
rats that received rotenone microspheres injection in the SC was
stained for ssDNA and cleaved forms of caspase. (a) ssDNA, (b)
cleaved form of caspase, (c) DAPI, (d) merge of the three images.
Control rats that received no rotenone did not exhibit positive
signals (not shown). Scale bar =40 mm.
Found at: doi:10.1371/journal.pone.0011472.s006 (0.51 MB TIF)
Movie S1 Optokinetic tests comparing between a rat treated
with roteone and a rat that received Ndi1 in addition to rotenone
treatment.
Found at: doi:10.1371/journal.pone.0011472.s007 (3.80 MB
MOV)
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